

Lauren C Harshman

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6049794/lauren-c-harshman-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

107
papers

2,982
citations

28
h-index

51
g-index

111
ext. papers

3,840
ext. citations

5.4
avg, IF

4.94
L-index

#	Paper	IF	Citations
107	Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma.. <i>JCO Precision Oncology</i> , 2022 , 6, e2100448	3.6	1
106	Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2021 ,	13.4	6
105	Treatment of Metastatic Urothelial Carcinoma After Previous Cisplatin-based Chemotherapy for Localized Disease: A Retrospective Comparison of Different Chemotherapy Regimens. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, 125-134	3.3	1
104	PROSPER: Phase III RandOmized Study Comparing PERioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS4596-TPS4596	2.2	1
103	Results of a phase 1 study of SRF388, a first-in-human, first-in-class, high-affinity anti-IL-27 antibody in advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2551-2551	2.2	1
102	Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. <i>Nature Communications</i> , 2021 , 12, 808	17.4	26
101	Activity and safety of cabozantinib (cabo) in brain metastases (BM) from metastatic renal cell carcinoma (mRCC): An international multicenter study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 310-310	2.2	5
100	Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study. <i>Clinical Cancer Research</i> , 2021 , 27, 3360-3369	12.9	17
99	Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy. <i>JAMA Network Open</i> , 2021 , 4, e2116536	10.4	4
98	Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma After Previous Platinum-Based Chemotherapy for Metastatic Disease. <i>Oncologist</i> , 2021 , 26, 1026-1034	5.7	1
97	IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC) 2021 , 9,		5
96	Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study 2020 , 8,		6
95	Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma. <i>European Journal of Cancer</i> , 2020 , 135, 203-210	7.5	28
94	Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors 2020 , 8,		8
93	Optimized management of nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma (RCC): A response-based phase II study (OMNIVORE).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5005-5005	2.2	14
92	Safety and overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) plus subsequent taxane therapy.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5542-5542	2.2	1
91	PROSPER: Phase III randomized study comparing perioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS5101-TPS5101	2.2	0

90	Treatment of metastatic recurrence of urothelial carcinoma after previous cisplatin-based chemotherapy: A retrospective comparison of different chemotherapy regimens.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e17005-e17005	2.2	
89	Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features. <i>Journal of Clinical Oncology</i> , 2020 , 38, 63-70	2.2	64
88	A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma. <i>British Journal of Cancer</i> , 2020 , 122, 555-563	8.7	28
87	Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma. <i>Genetics in Medicine</i> , 2020 , 22, 709-718	8.1	17
86	Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survival. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 934.e1-934.e9	2.8	0
85	Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma 2020 , 8,		8
84	Patterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHARTED Trial. <i>European Urology Oncology</i> , 2020 , 3, 717-724	6.7	3
83	Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE). <i>Journal of Clinical Oncology</i> , 2020 , 38, 4240-4248	2.2	27
82	Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib. <i>Clinical Cancer Research</i> , 2020 , 26, 6122-6131	12.9	4
81	Impact of baseline serum IL-8 on metastatic hormone-sensitive prostate cancer outcomes in the Phase 3 CHARTED trial (E3805). <i>Prostate</i> , 2020 , 80, 1429-1437	4.2	2
80	Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers. <i>European Urology Oncology</i> , 2020 , 3, 671-679	6.7	7
79	Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma. <i>European Urology Oncology</i> , 2020 , 3, 372-381	6.7	35
78	Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma 2020 , 8,		35
77	Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancer. <i>Cancer</i> , 2019 , 125, 3155-3163	6.4	15
76	Adjuvant Therapy Options in Renal Cell Carcinoma: Where Do We Stand?. <i>Current Treatment Options in Oncology</i> , 2019 , 20, 44	5.4	8
75	Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone. <i>Journal of Clinical Oncology</i> , 2019 , 37, 923-931 ^{2,2}		42
74	The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?. <i>Future Oncology</i> , 2019 , 15, 1683-1695	3.6	19
73	Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect. <i>European Urology</i> , 2019 , 76, 425-429	10.2	10

72	Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. <i>Lancet Oncology, The</i> , 2019 , 20, 581-590	21.7	81
71	Utility of FDG-PET/CT in Patients with Advanced Renal Cell Carcinoma with Osseous Metastases: Comparison with CT and 99mTc-MDP Bone Scan in a Prospective Clinical Trial. <i>Kidney Cancer</i> , 2019 , 3, 241-251	0.6	1
70	Anti-PD-1 Immunotherapy-Induced Flare of a Known Underlying Relapsing Vasculitis Mimicking Recurrent Cancer. <i>Oncologist</i> , 2019 , 24, 1013-1021	5.7	10
69	The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer. <i>Oncologist</i> , 2019 , 24, 1348-1355	5.7	7
68	Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites. <i>Clinical Cancer Research</i> , 2019 , 25, 2458-2470	12.9	52
67	Elevated Serum Cytokines and <i>Trichomonas vaginalis</i> Serology at Diagnosis Are Not Associated With Higher Gleason Grade or Lethal Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, 32-37	3.3	4
66	Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis. <i>European Urology Focus</i> , 2019 , 5, 242-249	5.1	6
65	Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events. <i>Cancer Immunology Research</i> , 2018 , 6, 402-408	12.5	42
64	Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial-level meta-analysis. <i>Cancer</i> , 2018 , 124, 925-933	6.4	21
63	Contemporary Patterns of Multidisciplinary Care in Patients With Muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, 213-218	3.3	10
62	Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). <i>Prostate</i> , 2018 , 78, 889-895	4.2	50
61	Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study. <i>European Urology Focus</i> , 2018 , 4, 937-945	5.1	6
60	Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e483-e490	3.3	8
59	Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators. <i>Acta Oncologica</i> , 2018 , 57, 491-497	3.2	14
58	Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma 2018 , 6, 5		129
57	The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma. <i>Cancer Immunology Research</i> , 2018 , 6, 758-765	12.5	66
56	A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer. <i>Prostate</i> , 2018 , 78, 1053	4.2	4
55	Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. <i>Journal of Clinical Oncology</i> , 2018 , 36, 376-382	2.2	40

54	Enrichment of FGFR3-TACC3 Fusions in Patients With Bladder Cancer Who Are Young, Asian, or Have Never Smoked. <i>JCO Precision Oncology</i> , 2018 , 2,	3.6	1
53	Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database. <i>Frontiers in Oncology</i> , 2018 , 8, 463	5.3	17
52	Investigating the effect of treatment at high-volume hospitals on overall survival following cytoreductive nephrectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 400.e15-400.e22 ¹	2.8	1
51	Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma. <i>British Journal of Cancer</i> , 2018 , 119, 707-712	8.7	18
50	Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis. <i>European Urology</i> , 2018 , 74, 611-620	10.2	49
49	Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor-Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases. <i>Clinical Cancer Research</i> , 2018 , 24, 4081-4088	12.9	17
48	Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival. <i>Cancer Medicine</i> , 2017 , 6, 186-194	4.8	10
47	Risk Assessment in Small Renal Masses: A Review Article. <i>Urologic Clinics of North America</i> , 2017 , 44, 189-202	2.9	3
46	Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder. <i>European Urology</i> , 2017 , 72, 483-487	10.2	65
45	Characterization of efficacy and toxicity after high-dose pelvic reirradiation with palliative intent for genitourinary second malignant neoplasms or local recurrences after full-dose radiation therapy in the pelvis: A high-volume cancer center experience. <i>Advances in Radiation Oncology</i> , 2017 , 2, 140-147	3.3	6
44	Prognostic Significance of Increases in Hemoglobin in Renal Cell Carcinoma Patients During Treatment With VEGF-directed Therapy. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 396-402	3.3	3
43	Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). <i>European Urology</i> , 2017 , 71, 281-289	10.2	41
42	Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series 2017 , 5, 66		27
41	Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffey-Holden Prostate Cancer Academy Meeting. <i>Prostate</i> , 2017 , 77, 1478-1488	4.2	2
40	The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer. <i>Prostate</i> , 2017 , 77, 1303-1311	4.2	11
39	The Khorana Score in Predicting Venous Thromboembolism for Patients With Metastatic Urothelial Carcinoma and Variant Histology Treated With Chemotherapy. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017 , 23, 755-760	3.3	13
38	Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression. <i>Oncotarget</i> , 2017 , 8, 103428-103436	3.3	13
37	Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2016 , 2, 405-413	1	6

36	Programmed cell death-1 pathway inhibitors in genitourinary malignancies: specific side-effects and their management. <i>Current Opinion in Urology</i> , 2016 , 26, 548-55	2.8	7
35	Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, e299-305	3.3	9
34	Association of SLCO2B1 Genotypes With Time to Progression and Overall Survival in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 352-9	2.2	28
33	Prognostic Value of Quantitative Metabolic Metrics on Baseline Pre-Sunitinib FDG PET/CT in Advanced Renal Cell Carcinoma. <i>PLoS ONE</i> , 2016 , 11, e0153321	3.7	5
32	A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies. <i>Cancer</i> , 2016 , 122, 2389-98	6.4	9
31	Phase II Study of Pazopanib and Paclitaxel in Patients With Refractory Urothelial Cancer. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, 432-437	3.3	12
30	Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer. <i>JAMA Oncology</i> , 2015 , 1, 495-504	13.4	87
29	Second-line therapies in metastatic urothelial carcinoma. <i>Hematology/Oncology Clinics of North America</i> , 2015 , 29, 341-59, x	3.1	4
28	Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. <i>Cancer</i> , 2015 , 121, 2586-93	6.4	120
27	Contemporary trends in high-dose interleukin-2 use for metastatic renal cell carcinoma in the United States. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 496.e11-6	2.8	31
26	Characteristics of long-term and short-term survivors of metastatic renal cell carcinoma treated with targeted therapies: results from the International mRCC Database Consortium. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 150-5	3.3	9
25	Diagnosis of Bladder Carcinoma: A Clinician's Perspective. <i>Surgical Pathology Clinics</i> , 2015 , 8, 677-85	3.9	14
24	Non-clear cell renal cell carcinoma, part 1: histology. <i>Clinical Advances in Hematology and Oncology</i> , 2015 , 13, 308-13	0.6	8
23	Non-clear cell renal cell carcinoma, part 2: therapy. <i>Clinical Advances in Hematology and Oncology</i> , 2015 , 13, 383-91	0.6	13
22	Elevated IL-8, TNF- α and MCP-1 in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival. <i>Prostate</i> , 2014 , 74, 820-8	4.2	53
21	First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, 335-40	3.3	7
20	PD-1 blockade in renal cell carcinoma: to equilibrium and beyond. <i>Cancer Immunology Research</i> , 2014 , 2, 1132-41	12.5	33
19	Harnessing the PD-1 pathway in renal cell carcinoma: current evidence and future directions. <i>BioDrugs</i> , 2014 , 28, 513-26	7.9	7

18	Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2014 , 20, 272-80	2.2	14
17	Prognostic risk stratification derived from individual patient level data for men with advanced penile squamous cell carcinoma receiving first-line systemic therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 501-8	2.8	25
16	Concurrent chemoradiotherapy for men with locally advanced penile squamous cell carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, 440-6	3.3	26
15	Abiraterone acetate: targeting persistent androgen dependence in castration-resistant prostate cancer. <i>Advances in Therapy</i> , 2013 , 30, 727-47	4.1	12
14	The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. <i>Targeted Oncology</i> , 2013 , 8, 203-209	5	45
13	External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. <i>Lancet Oncology, The</i> , 2013 , 14, 141-8	21.7	598
12	A phase II study of bevacizumab and everolimus as treatment for refractory metastatic renal cell carcinoma. <i>Clinical Genitourinary Cancer</i> , 2013 , 11, 100-6	3.3	20
11	The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients. <i>JACC: Heart Failure</i> , 2013 , 1, 72-8	7.9	134
10	Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC). <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013 , 31, 379-85	2.8	41
9	Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2013 , 19, 316-23	2.2	42
8	Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. <i>Lancet Oncology, The</i> , 2012 , 13, 927-35	21.7	104
7	Ribonucleotide reductase subunit M1 expression in resectable, muscle-invasive urothelial cancer correlates with survival in younger patients. <i>BJU International</i> , 2010 , 106, 1805-11	5.6	12
6	The bevacizumab experience in advanced renal cell carcinoma. <i>OncoTargets and Therapy</i> , 2010 , 3, 179-89	4.4	8
5	Impact of common medications on serum total prostate-specific antigen levels: analysis of the National Health and Nutrition Examination Survey. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3951-7	2.2	98
4	Increased hemoglobin associated with VEGF inhibitors in advanced renal cell carcinoma. <i>Cancer Investigation</i> , 2009 , 27, 851-6	2.1	14
3	The combination of thalidomide and capecitabine in metastatic renal cell carcinoma -- is not the answer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2008 , 31, 417-23	2.7	6
2	Increased Hemoglobin Associated with VEGF Inhibitors in Advanced Renal Cell Carcinoma. <i>Blood</i> , 2008 , 112, 3453-3453	2.2	
1	Current status of cytoreductive nephrectomy in metastatic renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2007 , 7, 1749-61	3.5	2

